De réir thorthaí staidéar trialach cliniciúil domhanda uathúil, d'fhéadfadh sé nach mbeadh ceimiteiripe caighdeánach sé mhí ag teastáil ó roinnt othar a bhfuil ailse drólainne céim III orthu a théann faoi resection máinliachta ar a gcuid siadaí agus nóid limfe tar éis ceimiteiripe. I gcodarsnacht leis sin, i gcás go leor othar íseal-riosca, ní chuireann trí mhí ceimiteiripe méadú suntasach ar an ráta atarlaithe ailse agus féadann sé fo-iarsmaí díobhálacha a chosc, lena n-áirítear damáiste nerve de bharr an oxaliplatin drugaí ceimiteiripe, nó pian buan, numbness agus griofadach .
This is a global trial launched in 2007 on the International Duration Assessment of Adjuvant Chemotherapy (IDEA). Six parallel Phase III trials in 12 countries in North America, Europe and Asia enrolled 12,834 eligible patients. Patients with stage III ailse drólainne usually use FOLFOX or CAPOX chemotherapy for standard treatment after surgery. The researchers randomly assigned patients to treatment groups of three or six months.
Results: Three months of chemotherapy is not suitable for all patients. Instead, the data shows that the duration of chemotherapy should be determined based on the combination of drugs used and the individual characteristics of the patient ’s cancer: the degree of meall deposition on the colon wall and the number of lymph nodes that the cancer has spread to. For low-risk patients-those with shallow tumors and affected lymph nodes-treatment with CAPOX for 3 months has been shown to be safe and effective, with little side effects, the same as the progression-free survival (PFS) of six months of treatment. However, in some cases, a six-month course of treatment is better for high-risk patients.
Dúirt an Dr Anthony Shields, ollamh i Scoil an Leighis Ollscoil Wayne State, go bhfuil na caighdeáin nua seo curtha i bhfeidhm agam go praiticiúil ar othair a bhfuil ailse drólainne íseal-riosca orthu, rud a shábhálann go leor ama cóireála dóibh agus a d’fhéadfadh cosc a chur ar thocsaineacht freisin. sé mhí d'éifeacht ceimiteiripe. Measann thart ar 400,000 othar ar fud an domhain cóireáil oxaliplatin-bhunaithe mar regimen ceimiteiripe iar-obráide, agus mar sin beidh tionchar mór ag na torthaí seo.
